Published in final edited form as:

Biochim Biophys Acta. 2009 April ; 1789(4): 250–260. doi:10.1016/j.bbagr.2008.07.013.

Structure and Evolution of the *C. elegans* Embryonic Endomesoderm Network

Morris F. Maduro*

Department of Biology, University of California, Riverside Riverside, CA 92521, (951) 827-7196, mmaduro@ucr.edu

Summary

The specification of the *C. elegans* endomesoderm has been the subject of study for more than 15 years. Specification of the 4-cell stage endomesoderm precursor, EMS, occurs as a result of the activation of a transcription factor cascade that starts with SKN-1, coupled with input from the Wnt/ β -catenin asymmetry pathway through the nuclear effector POP-1. As development proceeds, transient cell fate factors are succeeded by stable, tissue/organ-specific regulators. The pathway is complex and uses motifs found in all transcriptional networks. Here, the regulators that function in the *C. elegans* endomesoderm network are described. An examination of the motifs in the network suggests how they may have evolved from simpler gene interactions. Flexibility in the network is evident from the multitude of parallel functions that can be identified, and from an apparent change in parts of the corresponding network in *C. briggsae*. Overall, the complexities of *C. elegans* endomesoderm specification build a picture of a network that is robust, complex, and still evolving.

Keywords

C. elegans; endomesoderm; cell fate specification; gene network; development

1. Introduction

Triploblastic animals begin life as a single cell, which after many rounds of mitosis, will ultimately consist of a multitude of genetically equivalent cells. By adulthood, the majority of these will have selected a particular pathway of differentiation, each expressing a subset of the genes in the organism's genetic complement that uniquely defines its type. At some point in embryogenesis, precursor cells become specified, and acquire transcriptional differences that set them apart from their neighbors. These differences will instruct their descendants as to their ultimate cell type, or at least restrict their choices until a later time.

In the nematode, *C. elegans*, cells acquire these differences very early, as seen in the stereotyped cleavage patterns that are the hallmark of its nearly-invariant cell lineage [1]. The point of sperm entry sets the posterior of the embryo, defining one of the three embryonic axes (reviewed in [2]). The first division produces a larger cell, AB, and a smaller posterior cell, P₁. Following division of AB and P₁, the embryo consists of the anterior and posterior daughters of AB (ABa and ABp, respectively), and the two daughters of P₁, called EMS and P₂ (Fig. 1).

*Corresponding author. Tel.: 951-827-7196; fax: 951-827-4286. E-mail address: E-mail: mmaduro@ucr.edu (M.F. Maduro).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

EMS, situated ventrally, is an endomesoderm precursor: It will divide to produce a posterior daughter, called E, and an anterior daughter, MS. The E cell will clonally generate the 20 larval cells of the midgut (endoderm), while MS generates many cells that are primarily mesodermal, which includes most cells in the posterior half of the pharynx, and many of the animal's body muscles. The remaining portion of the pharynx is made by the anterior daughter of AB (ABa). Because many cells in the *C. elegans* lineage undergo anterior-posterior divisions to produce daughters that will acquire different fates, specification of MS and E is a platform for examining mechanisms that may operate throughout much of the animal's development.

Work over the past 15+ years has identified multiple factors that specify the *C. elegans* endomesoderm. Essentially, there are two pathways that converge on EMS specification: The SKN-1/MED-1,2 pathway assigns an endomesodermal fate to EMS, while the Wnt/ β -catenin asymmetry pathway makes E different from MS [3,4]. Although the pathways that lead to MS and E specification look superficially like a simple cascade, the network contains much subtlety, crosstalk, redundancy, and flexibility. This review will examine the genes that specify MS and E, how deployment of their developmental programs is restricted to the appropriate lineages, and how the overall network may be evolving. A diagrammatic summary of the information flow in the network is presented in Fig. 1.

2. The endomesoderm network

The rapid development of *C. elegans* is considered derived within the phylum, and the rapid divisions in the early embryo are proposed to be correlated with the use of maternal factors to drive much of the early cell specification events [5–7]. Screens for maternal embryonic lethals, in which arrested embryos lack one or more major tissue types but still contain many differentiated nuclei, led to the identification of multiple factors, including the gene *skn-1* [8].

2.1. Getting it all started: Maternal SKN-1 specifies EMS

Embryos from *skn-1(-)* mothers undergo a developmental arrest and lack pharynx 100% of the time, while endoderm is absent in approximately 70% of embryos [8]. Pharynx originates from descendants of both MS and ABa [1], and the absence of both AB- and MS-derived pharynx in *skn-1* mutant embryos is attributed to the failure of a GLP-1/Notch-mediated cell induction that occurs between the MS cell and descendants of ABa [8,9].

Antibody staining shows that SKN-1 protein is present in the EMS and P₂ nuclei at the 4-cell stage, placing it in the correct time and space to directly act in its specification [10]. As discussed below, SKN-1 does not act in P₂ due to the function of another maternal gene, *pie-1* [11–13]. The *skn-1* locus encodes a transcription factor that has domains similar to those found in bZIP and homeodomain proteins [14]. As its expression normally disappears during the MS and E cell cycles [10], SKN-1 is likely to be a factor that initiates a zygotic gene cascade that will specify MS and E. The observation that many *skn-1(-)* embryos still make endoderm points to the existence of parallel pathways that are capable of contributing to gut specification in the absence of SKN-1, and these will be discussed later.

2.2. Zygotic specification of endoderm by END-1 and END-3

Mutagenic screens for penetrant zygotic mutations that resulted in the absence of endoderm identified only a large genomic region on chromosome V, named the 'Endoderm Determining Region' or EDR [15]. EDR-deficient [EDR(Df)] embryos lack endoderm and show a transformation of E to a C-like cell [15]. Within a 30-kbp region located within the EDR, two GATA factor genes, *end-1* and *end-3*, were identified that could individually restore endoderm development to EDR(Df) embryos, suggesting that both genes share overlapping function [15,16]. Consistent with this, overexpression of either *end-1* or *end-3* can reprogram non-

endodermal cells into gut precursors [16,17]. Transgene fusion reporters for both genes are also expressed in the early E lineage, though expression goes away after several cell divisions [16,18]. Hence, *end-1* and *end-3* are clearly paralogous, likely having arisen from an ancient gene duplication [16].

Two observations suggest that *end-1* and *end-3* have diverged somewhat, which might account for their maintenance [19]. First, while a null mutation of *end-1* has no discernible phenotype, mutation of *end-3* results in a weak endoderm specification defect, and in those embryos making endoderm, the number of gut cells frequently deviates from the 20 normally seen in wild-type [16,20]. Second, both *in situ* hybridization studies and whole-embryo transcriptome experiments show that *end-3* is activated slightly earlier than *end-1* within the E cell cycle [20,21]. There is further genetic evidence, discussed below, that END-3 also contributes to activation of *end-1* [20].

Are there any other zygotic genes that specifically contribute to E specification? RNAi targeted to both *end-1* and *end-3* resulted in only approximately 43% of embryos that lacked gut, although this appears to be the result of a weak RNAi effect on *end-1* [16]. To resolve the question of whether or not other genes can specify endoderm in addition to *end-1* and *end-3*, we generated an *end-1(-) end-3(-)* strain using putative null mutants for both loci. All *end-1,3(-)* embryos lack differentiated endoderm (Fig. 2E), although the overall phenotype is surprisingly mild: Most embryos become enclosed in epidermis and undergo elongation, and some can hatch into arrested larvae as shown in Fig. 2B (M.M., unpublished results). This phenotype is very different from EDR(Df) embryos, which arrest well before elongation due to the simultaneous loss of many genes in addition to *end-1* and *end-3* [15,22].

The behavior of the early E lineage cells explains the mild *end-1,3(-)* phenotype. One of the properties of the early E lineage is that the two E daughter cells (Ea and Ep) move into the interior of the embryo, which marks the onset of gastrulation [23]. Examination of the movements of the early E descendants in *end-3(-)*, *end-1,3(-)* and EDR(Df) embryos, alone and in combination with Wnt pathway mutants, shows that Wnt components and the ENDS share overlapping function in gastrulation [15,16,23] [Jacob Sawyer and Bob Goldstein, personal communication]. Indeed, it has been proposed that in general, pathways that control morphogenesis will have greater redundancies than those that specify cell fate [24].

2.3. The MED-1 and MED-2 factors

The involvement of the GATA factors *end-1* and *end-3* in specification of E led to the hypothesis that a similar regulator might be responsible for specification of MS [25]. Searches of the partially-assembled *C. elegans* genome sequence led to the identification of *med-1* and *med-2*, two unlinked but nearly-identical putative GATA factors, that seemed to confirm this [25]. Rather than function in MS specification analogous to the *end* genes, however, the *med-1,2* genes appear to function ‘in between’ SKN-1 and *end-1,3*. RNA interference and double mutant studies with null alleles of both genes have shown that *med-1,2(-)* embryos lack MS-derived tissues all of the time, but also lack endoderm some of the time (15–50%) [3,25–27]. Unlike loss of *end-1,3*, *med* mutant embryos do not complete elongation and arrest before hatching. Reporter gene, gel shift and *in situ* hybridization studies showed that the *med* genes are activated in the EMS cell, and that this expression is transient [20,25]. Expression is dependent on interaction of SKN-1 with the *med* promoters, implying that SKN-1 directly activates *med-1,2* in EMS [20,25]. An additional *med-1,2* expression component occurs in the maternal germ line that also is dependent on SKN-1 [20]. The germline expression appears to account for the observation that embryos only zygotically lacking in *med-1,2* are more likely to specify endoderm, though these findings have been disputed by others based on indirect evidence [20,26].

Sufficiency experiments show that overexpression of *med-1* throughout the embryo results in widespread expression of *end-1::GFP* and *end-3::GFP* reporters, and embryonic lethality with excess pharynx muscle or endoderm [18,25]. These results suggest that *med-1* is sufficient to initiate a program of MS or E specification, perhaps in combination with other factors, and that with respect to endoderm, the MEDs function upstream of the *end* genes [25]. Terminal *med-1,2; end-1,3* quadruple mutant embryos (Fig. 2C) lack gut and arrest with an appearance similar to the most profoundly affected *med-1,2(-)* embryos, consistent with placement of *end-1,3* downstream of *med-1,2* [25]. The weak endoderm phenotype of *med-1,2(-)* embryos is consistent with involvement of parallel inputs into *end-1,3* activation, discussed later.

Additional evidence supports a role for MED-1,2 in activation of *end-1,3*. Both in vitro studies (DNaseI footprinting and gel shift assays) and in vivo experiments (visualization of subnuclear spots representing interaction of GFP-tagged MED-1 with target arrays) confirm a direct interaction of MED-1 with the promoters of *end-1* and *end-3* [28,29]. Two sites in *end-1*, and four in *end-3*, were identified as regions of MED-1 interaction [28]. Unexpectedly, MED-1 appears to not recognize a canonical GATA binding site (HGATAR), but rather a related sequence (RAGTATAC) [28,30].

There is some evidence that *med-1* and *med-2* are, like the *end-1,3* pair, not completely redundant. First, germline *med-2* mRNAs accumulate to apparently higher levels in a *med-1* (-) animal, than the reverse, although both show similar expression in EMS [20]. Second, of the four possible *med-x; end-y* double mutant combinations, only *med-1; end-3* demonstrates a synergistic effect, resulting in a ~58% gutless phenotype, and a high proportion of embryos containing less than the wild-type number of 20 gut cells [20]. In contrast, a *med-2; end-3* double mutant strain makes endoderm >95% of the time, similar to loss of *end-3* alone. Therefore, even though the *med* genes are undoubtedly the result of a recent duplication, they have nonetheless diverged [20,31].

2.4. MS specification and TBX-35

Under the hypothesis that MED-1,2 would likely bind putative MS regulators in the same manner as with the E targets *end-1,3*, the *C. elegans* genome sequence was searched for MED-1 binding site clusters, which identified (among other genes) *tbx-35*, a gene that contains seven putative MED-1 sites and which encodes a putative T-box transcription factor [28]. Consistent with *med-1,2*-dependent activation, *tbx-35* transcripts are found in the MS cell, and a *tbx-35::GFP* reporter is expressed in the early MS lineage [32]. *tbx-35* was also identified as an early MS-specific gene in a study that identified downstream embryonic targets of SKN-1 [33]. Recombinant MED-1 protein is able to shift fragments of the *tbx-35* promoter, consistent with a direct interaction [32]. Mutant *tbx-35(-)* animals undergo developmental arrest as embryos or larvae, with the most extremely affected animals demonstrating a profound lack of MS-derived pharynx and body wall muscle [32]. The variable phenotype contrasts with the more stereotyped embryonic arrest of *med-1,2(-)* embryos, suggesting that many *tbx-35(-)* embryos can still make MS-derived tissues. Consistent with the existence of factors that work in parallel with TBX-35, we have found that the four embryonically-derived coelomocytes, which normally arise from MS descendants [1], are still present in *tbx-35(-)* embryos [Melissa Owraghi and M.M., unpublished observations]. Consistent with an ability to promote MS specification, overexpression of TBX-35 leads to the appearance of ectopic pharynx and body muscle [32] as well as coelomocytes [M.O. and M.M, unpublished]. Therefore, while TBX-35 is clearly an important regulator in MS specification, there must be additional factors that work in parallel.

3. Restriction of SKN-1 activity to EMS

Just as there are factors that assure timely activation of lineage-specific specification genes, other gene products act to prevent inappropriate activity of such factors in other cells. In the endomesoderm, these factors all act, collectively, in three functions: To restrict SKN-1 activity to the EMS nucleus, to prevent its translation in inappropriate parts of the embryo (or in the germline), and to promote its timely degradation. Hence, these components do not act directly in the network but are nonetheless vital for assuring its deployment in the EMS lineage alone.

3.1. PIE-1 and MEX-1

One of the factors that restricts SKN-1 function is the maternal factor PIE-1 [12]. In embryos lacking *pie-1* function, P₂ develops like an EMS cell, generating SKN-1-dependent MS and E fates in its descendants [12]. Consistent with ectopic activation of the EMS specification pathway by the SKN-1 protein normally found in P₂, *pie-1* mutant embryos display ectopic activation of *med-1* and *end-3* reporters in P₂ descendants [16,25]. Whole-genome transcriptome analysis also detected elevated *med-1,2* and *end-1* transcripts in *pie-1* mutant embryos, consistent with ectopic activation of the pathway downstream of SKN-1 [34]. PIE-1 is a CCCH zinc finger protein that is found in the P lineage, and functions by inhibiting transcription, explaining how the SKN-1 in P₂ normally does not activate EMS development [13,35,36].

At the other end of the embryo, the maternal factor MEX-1 restricts appearance of ectopic MS-like fates by preventing appearance of high levels of SKN-1 protein in the early AB lineage [10,12,37]. In embryos lacking *mex-1* function, the AB granddaughters adopt MS-like fates, concomitant with ectopic expression of *med-1,2* and *tbx-35* [12,25,32,38]. As with *pie-1*, function of SKN-1 is required for the appearance of ectopic MS-derived tissues in *mex-1* mutant embryos, consistent with the ectopic activation of the normal MS specification pathway in the AB lineage [12]. MEX-1 is a CCCH-type zinc finger protein similar to PIE-1, and like PIE-1, is found in the P lineage, where it functions in PIE-1 localization [39]. Hence, the role of MEX-1 in preventing in AB-specific accumulation of SKN-1 is apparently indirect.

3.2. Regulation of OMA-1 degradation

A gain-of-function (gf) mutation in *oma-1*, a gene encoding another CCCH-type zinc finger protein, results in ectopic mis-specification of C, a somatic daughter of P₂ (Fig. 1), as an EMS-like cell [40]. In *oma-1(gf)* embryos, SKN-1 protein degradation is delayed compared with the wild type, and ectopic expression of a *med-1::GFP* reporter is observed in the early C lineage [40]. Other maternal proteins (e.g. PIE-1 and MEX-1) are found to perdure in *oma-1(gf)* embryos, consistent with a role for OMA-1 in negative regulation of timely degradation of cell fate specification factors in general [40]. A group of kinases (CDK-1, GSK-3, KIN-19 and MBK-2) has been identified that act upstream of OMA-1 [41,42]. Loss of function of any of these components results in stabilization of OMA-1 and an ectopic SKN-1-dependent, ectopic endoderm phenotype similar to *oma-1(gf)* [41,42]. Timely degradation of OMA-1 permits the proteolysis of cell fate determinants, dependent upon the Zinc Finger binding protein ZIF-1 [41]. These results provide an explanation for how loss of GSK-3 function was previously found to result in ectopic expression of a *med-1* reporter in the C lineage, and specification of Cp as an E-like cell [25,43]. As GSK-3 functions in post-embryonic regulation of SKN-1 nuclear localization, there may also be a more direct role for GSK-3 in regulation of SKN-1 activity in C, rather than only through regulation of OMA-1 stability [44].

3.3. Maintenance of germline totipotency

The germline must assure that cell fate pathways are not activated. Intestine-like cells have been observed within the germline in approximately 25% of animals lacking function of both

mex-3 and *gld-1*, genes that encode RNA-binding proteins that function as translational repressors [45]. Although the appearance of intestine-like cells was not specifically associated with ectopic activity of SKN-1, transdifferentiation of other somatic cell types in this background was correlated with ectopic activation of other known tissue regulators (e.g., *hlh-1* for body muscle, as discussed below), suggesting that this is likely to be the case [45].

4. Permissive functions for SKN-1 activity

Loss of function of either of two genes, *pos-1* and *spn-4*, results in defects in EMS specification [46,47]. In *pos-1* mutant embryos, SKN-1 localization appears normal, but *med-1::GFP* is not expressed [25,47]. *spn-4* mutants also show normal SKN-1 localization, but apparently normal activation of a *med-1* reporter, suggesting that *spn-4* plays a different role in EMS development [46]. As *pos-1* and *spn-4* mutants have a number of other developmental defects outside of the EMS lineage, their roles would appear to be more permissive for EMS specification [46,47]. Indeed, POS-1 and SPN-4 have been shown to interact, and have a role in regulating translation of maternal *glp-1* mRNA [48].

5. Making MS and E different

The genes described above participate in specification of EMS as an endomesodermal precursor, but not in choosing between the alternate fates of mesoderm and endoderm. To make an MS or E cell from EMS, the SKN-1 pathway works with an evolutionarily conserved switching system that acts on sister cells to specify their fates as different, through a signaling cascade that is now called the Wnt/ β -catenin asymmetry pathway [4,49].

5.1. The Wnt/ β -catenin asymmetry pathway and POP-1

When cultured in isolation, EMS divides asymmetrically to produce two MS-like cells, giving rise to excess pharynx muscle and no endoderm [50,51]. When EMS is allowed to contact P₂ before it divides, it becomes polarized, such that the side of EMS that was in contact with P₂ will become the E cell, while its sister becomes MS [51]. Screens for mutations that could produce the same phenotype in intact embryos identified components of overlapping Wnt, MAPK and Src pathways [43,52,53]. The Wnt ligand MOM-2 and the receptor tyrosine kinase MES-1 function in parallel in the interaction between P₂ and EMS, though in slightly different ways: While MOM-2 is required only in P₂, MES-1 functions in both P₂ and EMS in an apparent dynamic interaction between the two cells [43,53]. Through a network of downstream signal transduction, which also participates in the reorientation of the EMS spindle [54], the Wnt/MAPK and Src pathways ultimately converge on the differential localization and activity of the nuclear Wnt effector TCF/POP-1 [43,55–57]. *pop-1* was first identified by a maternal-effect mutation that results in the MS cell adopting the fate of E [58]. Antibody staining of POP-1 showed that it is widely expressed, and in sister cells that are born along an anterior-posterior cleavage axis, there is a higher level of POP-1 in the anterior daughter nucleus than the posterior one [59]. This ‘POP-1 asymmetry’ is the result of the nuclear export of POP-1 in Wnt-responsive cells [29,60]. In addition to the MS/E decision, POP-1 has been found to be involved in a number of asymmetric cell divisions, including those of the postembryonic T hypodermal blast cell [61], and the Z1 and Z4 somatic gonad precursor cells [62]. Recently, it has been shown that the reduced levels of POP-1 in Wnt-signaled cells permits POP-1 to form a bipartite activator with limiting concentrations of the divergent β -catenin SYS-1, which shows a reciprocal posterior-anterior asymmetry compared with POP-1 [63–65]. POP-1 thus forms part of a binary switching system that can establish transcriptional differences of lineage-specific factors.

5.2. Multiple functions for POP-1

How does POP-1 participate in the MS/E decision? The phenotype of *pop-1* loss is a transformation of MS to E, and the ectopically-specified MS blastomeres in *mex-1* and *pie-1* mutant embryos adopt an E-like fate when *pop-1* function is simultaneously lost [58]. These results suggest that the main function of POP-1 is to repress endoderm specification in MS. Indeed, *in situ* and transgene reporter assays show that *end-1* and *end-3* are activated in the MS and E lineages in *pop-1* mutant embryos [16,20,66]. A GFP-tagged form of POP-1 can interact in vivo with extrachromosomal arrays carrying the *end-1* or *end-3* promoters, suggesting that this repression is direct [29], and a repressor complex that includes the Groucho homolog UNC-37 mediates repression of *end-1* in MS [67].

Multiple studies have shown that POP-1 also promotes endoderm fate in the E cell in parallel with SKN-1 and MED-1,2. Genetically, depletion of *pop-1* greatly enhances the endoderm phenotype of *skn-1* and *med-1,2* mutants, suggesting that POP-1 functions in parallel with these factors to promote E fate [16,65,68]. Consistent with a role in activation of endoderm when these genes are not mutated, expression of multiple E-specific reporter transgenes, including *end-1* and *end-3*, occurs in both the MS and E lineages at reduced levels in *pop-1* mutants as compared with expression in wild types [66]. An *end-1::GFP* reporter requires optimal TCF/POP-1 binding sites to exhibit POP-1-dependent repression in MS and activation in E, confirming that POP-1 likely exerts its effects through direct interaction with *end-1* [66]. As predicted by association of SYS-1 with POP-1 to form a bipartite activator in E, depletion of *sys-1* significantly enhances the endoderm-defective phenotype of *skn-1* mutant embryos [64,65]. Accumulation of endogenous *end-1* transcripts is slightly reduced in *pop-1* mutant embryos, and almost eliminated in *end-3; pop-1* mutants, confirming overlapping roles of both POP-1 and END-3 in *end-1* activation in E [20]; as an aside, this synergistic effect on *end-1* activation is consistent with greatly enhanced gutlessness in *end-3; pop-1* mutants [16].

There is further evidence that POP-1 is capable of additional functions besides repression of endoderm in MS and contribution to activation of endoderm fate in E. Expression of a *tbx-35::GFP* reporter [33] is diminished in MS, and activated in E, in *pop-1* mutant embryos, suggesting that some gene(s) might be able to respond to POP-1 in a reciprocal manner from *end-1,3* [Premnath Shetty and Rueyling Lin, personal communication]. However, expression of endogenous *tbx-35* transcripts, and a slightly different *tbx-35::GFP* reporter, are apparently unaffected by loss of *pop-1*, suggesting that there may be additional nuclear factors that respond to Wnt signaling [32].

To test for a possible requirement for *pop-1* in MS specification beyond repression of *end-1,3*, we examined the phenotype of *end-1,3(-)* embryos in which *pop-1* function was eliminated by RNAi. Preliminary results suggest that both MS and E adopt some properties of MS in *pop-1(RNAi); end-1,3(-)* embryos, suggesting that POP-1 is not strictly required to initiate a program of MS development [Melissa Owraghi and M.M., unpublished observations]. The apparent adoption of MS-like properties by the E cell in such embryos contrasts with the penetrant transformation of E to C in *end-1,3(-)* embryos [15,16], and suggests a cryptic MS-repressive role for POP-1 in the E cell. Future work will no doubt shed light on these additional roles.

6. Moving from lineage- to tissue-based gene networks

As development proceeds, two types of specification mechanisms are thought to drive the process forward: Those that are lineage-based, in which mutation affects all descendants of a cell irrespective of the tissue types it produces, and those that are organ/tissue-based, in which mutation results in a defect in an entire organ/tissue irrespective of its lineal origin [69]. Global expression studies have identified several hundred genes activated in the pharynx [70], several

thousand in the intestine [71,72], and more than a thousand in muscle [73]. Activation of these tissue-specific networks results from the activation, in multiple lineages, of a small number of organ/tissue identity factors. In contrast with early cell fate specification genes, most of these factors remain activated through the lifespan of animal. These will be described only briefly below, as there are recent reviews that cover these networks [74–76].

6.1. Intestine fate: ELT-2 and gut identity

The GATA factor ELT-2 appears to be the intestine identity factor. *elt-2* expression begins in the E daughter cells, downstream of *end-1* and *end-3*, and continues through adulthood in all intestinal cells [16,17,77]. Consistent with the placement of ELT-2 at the very top of an intestine differentiation network, overexpression of *elt-2* can drive specification of gut throughout the embryo, similar to ectopically-expressed *end-1* or *end-3* [16,17,77], and it maintains its own expression through positive autoregulation [78]. Two independent studies found that the vast majority of genes that are activated in the intestine have a recognizable GATA binding site, with a core sequence of TGATAA [71,72]. Recombinant ELT-2 has been repeatedly shown to be able to interact with GATA sites required for ELT-2-dependent expression of numerous intestinal genes, for example *ges-1*, *fm-1*, *pho-1* and the intestine-specific, Notch-dependent component of *ref-1* [79–82]. *elt-2* has also been shown to be required for an innate immune response to microbial pathogens such as *Pseudomonas* [83,84].

Within the intestine, ELT-2 works in combination with other genes to generate more restricted patterns of gene expression, either autonomously within the gut, or as a result of external inductions. For example, ELT-2 and POP-1 appear to collaborate to restrict expression of *pho-1* to the posterior gut, or for anterior-specific expression of a deleted *ges-1* promoter::reporter construct [81,85]. An increase in the SYS-1::POP-1 ratio by an early E-lineage transgene can result in changes in anterior *pho-1* expression consistent with a role of the Wnt/ β -catenin asymmetry pathway in patterning expression within the gut [64]. Extrinsic cell signaling also interacts with gut-intrinsic factors, as Notch signaling and ELT-2 collaborate to activate expression of *ref-1* in the left side of the primordial gut at the 4E and 8E stages, and the right side at the 16E stage [79].

There is evidence that, at least in the embryo, ELT-2 activates intestinal development with at least one other gene: Loss of *elt-2* does not prevent gut formation in the embryo, though it does result in larval lethality from a failure to maintain gut integrity [77]. In earlier models of the endoderm specification pathway, it was hypothesized that another intestinal GATA factor, ELT-7, might work in parallel with ELT-2 in the early embryo [18]. This hypothesis made sense in light of the fact that *elt-7* is apparently coexpressed with *elt-2* through adulthood [18]. However, loss of either *elt-7* or *elt-4* (a partial duplication of *elt-2*) does not detectably affect intestine development, and only a slight enhancement of the *elt-2* phenotype is evident in an *elt-2*; *elt-7* double mutant, not a complete loss of gut [72]. Instead, perdurance of END-1 or END-3, or both, might be responsible for activating early expression of downstream intestine-specific factors [74]. This is plausible, as *glo-1* and *pgp-2*, both of which function in gut granule biogenesis, commence transgene expression in the two E daughter cells prior to activation of an *elt-2* reporter, suggesting that at least some gut-specific ‘differentiation’ factors are targets of END-1,3 [77,86,87]. As these regulators are all GATA factors, they would be expected to be able to bind to the same target sites. Hence, early intestine gene expression could be initiated by END-1/3 and ELT-2, and maintained by ELT-2 later, with some function contributed by ELT-7.

6.2. MS and pharynx, body muscle fates

Unlike E, the MS blastomere generates descendants of very different types, including pharynx cells, body muscle cells, the four embryonically-derived coelomocytes, the somatic gonad

precursors Z1 and Z4, and even some neurons [1]. The gene networks that drive specification of these various cell types are undoubtedly complex, though there are two major differentiation pathways that can be considered: Of the 80 cells made by MS in the embryo, 28 are body muscle cells and 31 are pharynx cells, which together comprise the majority of the embryonic MS descendants [1].

The regulator FoxA/PHA-4 was identified by mutations that resulted in the absence of pharynx [88,89]. Consistent with the placement of PHA-4 at the top of a network that specifies pharynx fate, ectopic PHA-4 is sufficient to induce formation of ectopic pharynx tissue [88]. *pha-4* is also expressed throughout the intestine and rectum (Fig. 2), and is required for rectum development, though *pha-4* loss does not profoundly affect gut development [89]. The pharynx itself contains numerous cell types, which includes muscles, neurons and epithelia [76], implying that there are additional factors that work with PHA-4 to generate the pharynx. Within pharynx muscle, the gene *myo-2*, which encodes a pharynx-specific myosin isoform, is regulated by distinct *cis*-regulatory modules that function within distinct pharynx muscle groups [90]. Both PHA-4 and the homeodomain transcription factor CEH-22 recognize *cis*-regulatory sites in *myo-2*, but whereas *pha-4* is expressed throughout the pharynx, *ceh-22* is activated only in pharynx muscle [89,91]. Another factor, PEB-1, is found both within and outside the pharynx, but also contributes directly to *myo-2* regulation [92]. The pharynx gland-specific gene *hlh-6* contains three regulatory elements, one of which binds PHA-4, and all three *cis*-regulatory modules work in concert to produce cell type-specific activation [93]. Multiple other pharynx regulators have been identified, suggesting that pharynx organogenesis in general involves the activation of many complex sub-networks [70,76,94].

Development of body muscles has been shown to be the result of three-way redundancy among the factors HLH-1, HND-1 and UNC-120 [34,95,96]. Consistent with overlapping function, loss of any one of these factors produces only mild muscle phenotypes, but loss of all three together results in a profound failure of muscle specification [95]. Similarly, overexpression of *hlh-1*, *hnd-1* or *unc-120* can specify cells as muscle precursors [95,97]. Within the C lineage, the factor Caudal/PAL-1 is proposed to activate zygotic *pal-1*, which activates a ‘muscle module’ consisting of *hnd-1*, *unc-120* and *hlh-1*, specifying muscle progenitors [34,75,95]. HND-1 is proposed to act in early embryogenesis, participating in activation of *hlh-1*, while *hlh-1* and *unc-120* act later, mutually enforcing their expression [75]. Enrichment of embryonic muscle genes has identified more than 1300 muscle-enriched genes, suggesting that just as with pharynx and intestine, there are complex sub-networks that remain to be identified [98].

The basis for how the muscle and pharynx tissue networks are activated in appropriate MS-derived precursors, downstream of MED-1/2 and TBX-35, are not yet fully understood. It is likely that the Wnt/ β -catenin asymmetry pathway plays a role based on multiple observations. First, POP-1 asymmetry is found in the MS daughters and grand-daughters [29,59], and lower levels of POP-1 are permissive for specification of muscle fates by ectopic HLH-1 [97]. Second, transgenic SYS-1 in the early MS lineage can produce apparent MSa to MSP fate transformations that are manifested as changes in muscle fates within the pharynx [64]. Third, loss of the divergent β -catenin WRM-1, required for Wnt-dependent modification of POP-1, causes defects within the MS lineage [52]: Mutants in *lit-1*, a gene whose product works with WRM-1 to modify POP-1, show posterior-to-anterior transformations in multiple lineages, including MS [99]. These transformations are consistent with a fourfold, rather than twofold, increase in the number of *ceh-22::GFP*-expressing cells produced from E+MS in *wrm-1* (*RNAi*) embryos [32].

Analogous to the MS/E decision, there must be factors that work in combination with the Wnt/ β -catenin asymmetry pathway to segregate fate potential within the early MS lineage. The C cell, cousin to MS and E, generates primarily muscle fates among its posterior granddaughters

(Cxp), similar to the muscle fates made by the MS posterior granddaughters (MSxp) [1]. PAL-1, which normally promotes C fate, is found in the early MS and E lineages as well [68,100]. An intriguing possibility, therefore, is that PAL-1 contributes to muscle specification in the MS lineage. Other candidates for such factors might also be found among the genes identified by their expression in the early EMS lineage [21,33].

7. Conservation of endomesoderm genes among nematodes

In perhaps the most well-characterized gene regulatory network, that of the sea urchin endomesoderm [101], evolutionary changes are driven by mutations in *cis*-regulatory sites [102]. This phenomenon seems to be generalizable as in multiple taxa, there are many examples of evolution being driven by changes in *cis*-regulatory sites [103]. Based on the extant *C. elegans* endomesoderm network, is it possible to make any conclusions about how it may have evolved? In a recent review, homologs of genes in the network were sought using genome sequence information from related species [3]. In the nematodes *Haemonchus contortus* and *Brugia malayi*, maternal factors and tissue/organ identity factors were found to be the most conserved [3]. This might be expected, as SKN-1 and POP-1, have additional roles in the animal [49,59,104], and the organ identity factors (e.g. PHA-4, ELT-2) have so many targets that it would seem unlikely that their functions could be transferred to another regulator. There are substantial differences in the way nematodes apportion fates to early blastomeres, although later embryogenesis tends to be more similar [7]. For example, in *Romanomermis*, it is the AB blastomere that produces gut [105], while in *Acrobeloides*, endoderm fate can be reassigned to another blastomere if the AB cell is ablated [106]. These differences mean that gene networks upstream of tissue/organ identity factors would be expected to be the most divergent among nematode species.

Within the 'Elegans group' in the *Caenorhabditis* genus (*elegans*, *briggsae*, *sp. 5*, *remanei*, and *brenneri*), there are in most cases one-to-one homologs for all the known genes in the endomesoderm network, although duplications appear to be occurring more frequently among the early zygotic regulators [3,107]. For example, *elt-4* is a partial duplication of *elt-2* that is found only within *C. elegans*, and *C. briggsae* carries a very recent, inverted duplication of *end-3* [16,108]. In the nematode *Pristionchus pacificus* there appears to be a pair of linked *end*-like genes whose transcripts accumulate in the early E lineage, suggesting that the *end-1,3* pair is at least as old as the time to the common ancestor of *Caenorhabditis* and *Pristionchus* (George Hsu and M.M., unpublished).

The *med* genes show a unique pattern of evolution. First, outside of *Caenorhabditis*, there are no known *med*-like GATA factor genes at all, suggesting that they evolved very recently [31]. Second, all known *med* genes are intronless [31]. Third, in contrast to the other nematode GATA factors, the *meds* are undergoing rapid duplications: While *C. elegans* has only two *med* paralogs, the *meds* in *C. remanei* number at least seven genes, and in *C. briggsae*, at least three [31]. There is no reason to think that the frequency of duplications of *med* genes should be any different than other genes in the network, suggesting that some other selective pressure, as yet unknown, is maintaining the duplicates.

8. Evolution of the network

With the limited studies done in other nematodes, it is premature to make any conclusions about how connectivity, gene hierarchies and robustness arose in the *C. elegans* endomesoderm network. Here, we will speculate as to how parts of the network might have evolved by gene duplication and loss/gain of transcription factor binding sites, and mention evidence for flexibility in how the Wnt/ β -catenin asymmetry pathway functions in the MS/E decision.

8.1. Intercalation of genes into a pathway

Studies of gene networks in other systems find that particular types of local connections, or motifs, occur at a high frequency [109]. Within the *C. elegans* endomesoderm network, many of these types of motifs, such as the regulatory chain motif, can be found [3]. Based on recent studies of motif evolution in the yeast transcriptional network [110], two speculative models are presented below to account for the formation of two motifs within the *C. elegans* endomesoderm network (Fig. 3). The evolutionary changes proposed are plausible based on findings in other systems [102,103,110].

Consider first the regulatory chain of SKN-1 activating *med-1,2*, which then leads to activation of *tbx-35* (Fig. 3A) [32]. Given that the *meds* are not found outside of *Caenorhabditis*, the ancestral pathway might very well have been direct activation of *tbx-35* by SKN-1. If a *med*-like gene arose from duplication of a GATA factor, this gene could have acquired sites for SKN-1, forming a single-input motif. Next, *tbx-35* could have acquired sites that allowed it to be recognized by the MED product, forming a feed-forward motif. If *tbx-35* then lost the original sites for SKN-1, while the number of sites for MED-1 was increased, the result would be the regulatory chain SKN-1 → MED-1 → TBX-35. Duplication of *med-1* would result in the extant pathway in *C. elegans*.

Next, consider the feed-forward loop whereby SKN-1 activity leads to activation of *end-3*, and SKN-1 and END-3 together activate *end-1* (Fig. 3B) [20]. By analogy to the first example, the ancestral pathway could be taken to be SKN-1 activating a single ancestral *end* gene directly. A duplication of the ancestral *end* gene occurs. If one of the *end* genes then acquires additional sites for positive autoregulation, a feed-forward loop can be established. The intercalation of MED-1,2 could have occurred prior to *end* duplication (similar to the example above), or afterwards, to produce the relationships in the extant network.

8.2. Evidence for flexibility in how POP-1 influences the MS/E decision

In the above examples, the initial input (SKN-1) and final output (MS or E specification) remain the same after the pathways have undergone changes, and the evolutionary steps required to change motif types are simple enough that they might occur over short time periods. Post-embryonically, changes in relative importance of overlapping signal transduction pathways has been demonstrated in the vulval lineages, despite no apparent differences in developmental output, suggesting that such informational connectivity changes can and do occur [111].

We have begun to look for cryptic differences in the endomesoderm network in *C. briggsae*. *C. elegans* and the related species *C. briggsae* diverged approximately 100 million years ago, but their embryonic cell lineages have remained highly similar [112,113]. Both genomes encode a single *pop-1* orthologue. While loss of *pop-1* in *C. elegans* leads to a mis-specification of MS as an E-like cell [58], RNA interference of *C. briggsae pop-1* leads to a loss of endoderm, and an apparent transformation of E to an MS-like cell [Katy Lin and M.M., results to be reported elsewhere]. Surprisingly, the two *end-3* paralogues in *C. briggsae* are not expressed ectopically in the MS lineage in *Cb-pop-1(RNAi)* embryos, and are in fact almost undetectable compared with wild-type embryos [Gina Broitman-Maduro and M.M., unpublished]. One explanation is that the positive input by POP-1 into endoderm specification, apparent in *C. elegans* only under certain conditions, is now a primary input in *C. briggsae*. Similarly, the role for POP-1 in repression of the *end* genes in MS might simply have been lost, if the *Cb-end* genes were no longer as responsive to the SKN-1 pathway due to changes in *cis*-regulatory sites. Regardless of the molecular details, it is clear that there is flexibility in how factors such as POP-1 participate in the same embryonic cell fate decision in related species. In other developmental events in nematodes, such differences thought to underlie the basis for

robustness [114]. The prediction is that other such cryptic differences in phenotypes will be discovered as more comparative studies are performed.

9. Conclusion

When it comes to gene regulatory networks, the *C. elegans* embryonic endomesoderm network seems to have it all. Gene interactions have been characterized by forward genetics, reverse genetics, whole-genome transcriptional profiling, bioinformatics, transgene analysis and biochemistry. The network is replete with parallel pathways, redundant genes, combinatorial specification, feed-forward loops, regulatory chains, maternal genes, zygotic genes, repression, activation, cell-autonomous mechanisms and cell-cell interactions. Parallel pathways and redundancies almost certainly contribute to the robustness of the network, and they also enable alternate gene interactions to arise over time, even in the absence of any obvious outward phenotypic change. Other gene networks tend to use similar motifs and gene interactions, e.g. [109,115,116], suggesting that comparative studies with *C. elegans* and other related animals will yield new insights into their evolution. More specifically, it will be interesting to compare embryonic gene regulatory networks from related animals outside the nematode phylum, to test hypotheses of the mechanisms seem to be the main driving forces within the protostomes. To this end, studies in other ecdysozoa that partition fates early, such as the tardigrade *Hypsibius dujardini*, may prove fruitful [117].

References

1. Sulston JE, Schierenberg E, White JG, Thomson JN. The embryonic cell lineage of the nematode *Caenorhabditis elegans*. *Dev Biol* 1983;100:64–119. [PubMed: 6684600]
2. Gonczy P, Rose LS. Asymmetric cell division and axis formation in the embryo. *WormBook* 2005:1–20. [PubMed: 18050411]
3. Maduro MF. Endomesoderm specification in *Caenorhabditis elegans* and other nematodes. *Bioessays* 2006;28:1010–1022. [PubMed: 16998834]
4. Mizumoto K, Sawa H. Cortical beta-catenin and APC regulate asymmetric nuclear beta-catenin localization during asymmetric cell division in *C. elegans*. *Dev Cell* 2007;12:287–299. [PubMed: 17276345]
5. Schierenberg E. Three sons of fortune: early embryogenesis, evolution and ecology of nematodes. *Bioessays* 2001;23:841–847. [PubMed: 11536296]
6. Laugsch M, Schierenberg E. Differences in maternal supply and early development of closely related nematode species. *Int J Dev Biol* 2004;48:655–662. [PubMed: 15470638]
7. Schierenberg E. Embryological variation during nematode development. *WormBook* 2006:1–13. [PubMed: 18050475]
8. Bowerman B, Eaton BA, Priess JR. *skn-1*, a maternally expressed gene required to specify the fate of ventral blastomeres in the early *C. elegans* embryo. *Cell* 1992;68:1061–1075. [PubMed: 1547503]
9. Priess JR, Schnabel H, Schnabel R. The *glp-1* locus and cellular interactions in early *C. elegans* embryos. *Cell* 1987;51:601–611. [PubMed: 3677169]
10. Bowerman B, Draper BW, Mello CC, Priess JR. The maternal gene *skn-1* encodes a protein that is distributed unequally in early *C. elegans* embryos. *Cell* 1993;74:443–452. [PubMed: 8348611]
11. Bowerman B. Determinants of blastomere identity in the early *C. elegans* embryo. *Bioessays* 1995;17:405–414. [PubMed: 7786286]
12. Mello CC, Draper BW, Krause M, Weintraub H, Priess JR. The *pie-1* and *mex-1* genes and maternal control of blastomere identity in early *C. elegans* embryos. *Cell* 1992;70:163–176. [PubMed: 1623520]
13. Mello CC, Schubert C, Draper B, Zhang W, Lobel R, Priess JR. The *PIE-1* protein and germline specification in *C. elegans* embryos. *Nature* 1996;382:710–712. [PubMed: 8751440]
14. Blackwell TK, Bowerman B, Priess JR, Weintraub H. Formation of a monomeric DNA binding domain by *Skn-1* bZIP and homeodomain elements. *Science* 1994;266:621–628. [PubMed: 7939715]

15. Zhu J, Hill RJ, Heid PJ, Fukuyama M, Sugimoto A, Priess JR, Rothman JH. end-1 encodes an apparent GATA factor that specifies the endoderm precursor in *Caenorhabditis elegans* embryos. *Genes Dev* 1997;11:2883–2896. [PubMed: 9353257]
16. Maduro M, Hill RJ, Heid PJ, Newman-Smith ED, Zhu J, Priess J, Rothman J. Genetic redundancy in endoderm specification within the genus *Caenorhabditis*. *Dev Biol* 2005;284:509–522. [PubMed: 15979606]
17. Zhu J, Fukushige T, McGhee JD, Rothman JH. Reprogramming of early embryonic blastomeres into endodermal progenitors by a *Caenorhabditis elegans* GATA factor. *Genes Dev* 1998;12:3809–3814. [PubMed: 9869634]
18. Maduro MF, Rothman JH. Making worm guts: the gene regulatory network of the *Caenorhabditis elegans* endoderm. *Dev Biol* 2002;246:68–85. [PubMed: 12027435]
19. Force A, Lynch M, Pickett FB, Amores A, Yan YL, Postlethwait J. Preservation of duplicate genes by complementary, degenerative mutations. *Genetics* 1999;151:1531–1545. [PubMed: 10101175]
20. Maduro MF, Broitman-Maduro G, Mengarelli I, Rothman JH. Maternal deployment of the embryonic SKN-1-->MED-1,2 cell specification pathway in *C. elegans*. *Dev Biol* 2007;301:590–601. [PubMed: 16979152]
21. Baugh LR, Hill AA, Slonim DK, Brown EL, Hunter CP. Composition and dynamics of the *Caenorhabditis elegans* early embryonic transcriptome. *Development* 2003;130:889–900. [PubMed: 12538516]
22. Terns RM, Kroll-Conner P, Zhu J, Chung S, Rothman JH. A deficiency screen for zygotic loci required for establishment and patterning of the epidermis in *Caenorhabditis elegans*. *Genetics* 1997;146:185–206. [PubMed: 9136010]
23. Lee JY, Marston DJ, Walston T, Hardin J, Halberstadt A, Goldstein B. Wnt/Frizzled signaling controls *C. elegans* gastrulation by activating actomyosin contractility. *Curr Biol* 2006;16:1986–1997. [PubMed: 17055977]
24. Wieschaus, E. From molecular patterns to morphogenesis: The lessons from *Drosophila*. In: Ringertz, N., editor. Nobel Lectures, Physiology or Medicine. World Scientific Publishing Co; Singapore: 1995. p. 1991-1995.
25. Maduro MF, Meneghini MD, Bowerman B, Broitman-Maduro G, Rothman JH. Restriction of mesendoderm to a single blastomere by the combined action of SKN-1 and a GSK-3beta homolog is mediated by MED-1 and -2 in *C. elegans*. *Mol Cell* 2001;7:475–485. [PubMed: 11463373]
26. Captan VV, Goszczynski B, McGhee JD. Neither maternal nor zygotic med-1/med-2 genes play a major role in specifying the *Caenorhabditis elegans* endoderm. *Genetics* 2007;175:969–974. [PubMed: 17151237]
27. Goszczynski B, McGhee JD. Re-evaluation of the role of the med-1 and med-2 genes in specifying the *C. elegans* endoderm. *Genetics*. 2005
28. Broitman-Maduro G, Maduro MF, Rothman JH. The noncanonical binding site of the MED-1 GATA factor defines differentially regulated target genes in the *C. elegans* mesendoderm. *Dev Cell* 2005;8:427–433. [PubMed: 15737937]
29. Maduro MF, Lin R, Rothman JH. Dynamics of a developmental switch: recursive intracellular and intranuclear redistribution of *Caenorhabditis elegans* POP-1 parallels Wnt-inhibited transcriptional repression. *Dev Biol* 2002;248:128–142. [PubMed: 12142026]
30. Lowry JA, Atchley WR. Molecular evolution of the GATA family of transcription factors: conservation within the DNA-binding domain. *J Mol Evol* 2000;50:103–115. [PubMed: 10684344]
31. Coroian C, Broitman-Maduro G, Maduro MF. Med-type GATA factors and the evolution of mesendoderm specification in nematodes. *Dev Biol* 2005;289:444–455. [PubMed: 16325171]
32. Broitman-Maduro G, Lin KTH, Hung W, Maduro M. Specification of the *C. elegans* MS blastomere by the T-box factor TBX-35. *Development* 2006;133:3097–3106. [PubMed: 16831832]
33. Robertson SM, Shetty P, Lin R. Identification of lineage-specific zygotic transcripts in early *Caenorhabditis elegans* embryos. *Dev Biol* 2004;276:493–507. [PubMed: 15581881]
34. Baugh LR, Hill AA, Claggett JM, Hill-Harfe K, Wen JC, Slonim DK, Brown EL, Hunter CP. The homeodomain protein PAL-1 specifies a lineage-specific regulatory network in the *C. elegans* embryo. *Development* 2005;132:1843–1854. [PubMed: 15772128]

35. Tenenhaus C, Schubert C, Seydoux G. Genetic requirements for PIE-1 localization and inhibition of gene expression in the embryonic germ lineage of *Caenorhabditis elegans*. *Dev Biol* 1998;200:212–224. [PubMed: 9705228]
36. Ghosh D, Seydoux G. Inhibition of Transcription by the *Caenorhabditis elegans* Germline Protein PIE-1: Genetic Evidence for Distinct Mechanisms Targeting Initiation and Elongation. *Genetics* 2008;178:235–243. [PubMed: 18202370]
37. Seydoux G, Fire A. Whole-mount in situ hybridization for the detection of RNA in *Caenorhabditis elegans* embryos. *Methods Cell Biol* 1995;48:323–337. [PubMed: 8531733]
38. Schnabel R, Weigner C, Hutter H, Feichtinger R, Schnabel H. *mex-1* and the general partitioning of cell fate in the early *C. elegans* embryo. *Mech Dev* 1996;54:133–147. [PubMed: 8652407]
39. Guedes S, Priess JR. The *C. elegans* MEX-1 protein is present in germline blastomeres and is a P granule component. *Development* 1997;124:731–739. [PubMed: 9043088]
40. Lin R. A gain-of-function mutation in *oma-1*, a *C. elegans* gene required for oocyte maturation, results in delayed degradation of maternal proteins and embryonic lethality. *Dev Biol* 2003;258:226–239. [PubMed: 12781695]
41. Shirayama M, Soto MC, Ishidate T, Kim S, Nakamura K, Bei Y, van den Heuvel S, Mello CC. The Conserved Kinases CDK-1, GSK-3, KIN-19, and MBK-2 Promote OMA-1 Destruction to Regulate the Oocyte-to-Embryo Transition in *C. elegans*. *Curr Biol* 2006;16:47–55. [PubMed: 16343905]
42. Nishi Y, Lin R. DYRK2 and GSK-3 phosphorylate and promote the timely degradation of OMA-1, a key regulator of the oocyte-to-embryo transition in *C. elegans*. *Dev Biol* 2005;288:139–149. [PubMed: 16289132]
43. Bei Y, Hogan J, Berkowitz LA, Soto M, Rocheleau CE, Pang KM, Collins J, Mello CC. SRC-1 and Wnt signaling act together to specify endoderm and to control cleavage orientation in early *C. elegans* embryos. *Dev Cell* 2002;3:113–125. [PubMed: 12110172]
44. An JH, Vranas K, Lucke M, Inoue H, Hisamoto N, Matsumoto K, Blackwell TK. Regulation of the *Caenorhabditis elegans* oxidative stress defense protein SKN-1 by glycogen synthase kinase-3. *Proc Natl Acad Sci U S A* 2005;102:16275–16280. [PubMed: 16251270]
45. Ciosk R, DePalma M, Priess JR. Translational regulators maintain totipotency in the *Caenorhabditis elegans* germline. *Science* 2006;311:851–853. [PubMed: 16469927]
46. Gomes JE, Encalada SE, Swan KA, Shelton CA, Carter JC, Bowerman B. The maternal gene *spn-4* encodes a predicted RRM protein required for mitotic spindle orientation and cell fate patterning in early *C. elegans* embryos. *Development* 2001;128:4301–4314. [PubMed: 11684665]
47. Tabara H, Hill RJ, Mello CC, Priess JR, Kohara Y. *pos-1* encodes a cytoplasmic zinc-finger protein essential for germline specification in *C. elegans*. *Development* 1999;126:1–11. [PubMed: 9834181]
48. Ogura K, Kishimoto N, Mitani S, Gengyo-Ando K, Kohara Y. Translational control of maternal *glp-1* mRNA by POS-1 and its interacting protein SPN-4 in *Caenorhabditis elegans*. *Development* 2003;130:2495–2503. [PubMed: 12702662]
49. Schneider SQ, Bowerman B. beta-Catenin asymmetries after all animal/vegetal- oriented cell divisions in *Platynereis dumerilii* embryos mediate binary cell-fate specification. *Dev Cell* 2007;13:73–86. [PubMed: 17609111]
50. Goldstein B. Induction of gut in *Caenorhabditis elegans* embryos. *Nature* 1992;357:255–257. [PubMed: 1589023]
51. Goldstein B. Establishment of gut fate in the E lineage of *C. elegans*: the roles of lineage-dependent mechanisms and cell interactions. *Development* 1993;118:1267–1277. [PubMed: 8269853]
52. Rocheleau CE, Downs WD, Lin R, Wittmann C, Bei Y, Cha YH, Ali M, Priess JR, Mello CC. Wnt signaling and an APC-related gene specify endoderm in early *C. elegans* embryos. *Cell* 1997;90:707–716. [PubMed: 9288750]
53. Thorpe CJ, Schlesinger A, Carter JC, Bowerman B. Wnt signaling polarizes an early *C. elegans* blastomere to distinguish endoderm from mesoderm. *Cell* 1997;90:695–705. [PubMed: 9288749]
54. Schlesinger A, Shelton CA, Maloof JN, Meneghini M, Bowerman B. Wnt pathway components orient a mitotic spindle in the early *Caenorhabditis elegans* embryo without requiring gene transcription in the responding cell. *Genes Dev* 1999;13:2028–2038. [PubMed: 10444600]

55. Meneghini MD, Ishitani T, Carter JC, Hisamoto N, Ninomiya-Tsuji J, Thorpe CJ, Hamill DR, Matsumoto K, Bowerman B. MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in *Caenorhabditis elegans*. *Nature* 1999;399:793–797. [PubMed: 10391246]
56. Shin TH, Yasuda J, Rocheleau CE, Lin R, Soto M, Bei Y, Davis RJ, Mello CC. MOM-4, a MAP kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in *C. elegans*. *Mol Cell* 1999;4:275–280. [PubMed: 10488343]
57. Thorpe CJ, Schlesinger A, Bowerman B. Wnt signalling in *Caenorhabditis elegans*: regulating repressors and polarizing the cytoskeleton. *Trends Cell Biol* 2000;10:10–17. [PubMed: 10603471]
58. Lin R, Thompson S, Priess JR. pop-1 encodes an HMG box protein required for the specification of a mesoderm precursor in early *C. elegans* embryos. *Cell* 1995;83:599–609. [PubMed: 7585963]
59. Lin R, Hill RJ, Priess JR. POP-1 and anterior-posterior fate decisions in *C. elegans* embryos. *Cell* 1998;92:229–239. [PubMed: 9458047]
60. Lo MC, Gay F, Odom R, Shi Y, Lin R. Phosphorylation by the beta-catenin/MAPK complex promotes 14-3-3-mediated nuclear export of TCF/POP-1 in signal-responsive cells in *C. elegans*. *Cell* 2004;117:95–106. [PubMed: 15066285]
61. Arata Y, Kouike H, Zhang Y, Herman MA, Okano H, Sawa H. Wnt signaling and a Hox protein cooperatively regulate *psa-3/Meis* to determine daughter cell fate after asymmetric cell division in *C. elegans*. *Dev Cell* 2006;11:105–115. [PubMed: 16824957]
62. Siegfried KR, Kimble J. POP-1 controls axis formation during early gonadogenesis in *C. elegans*. *Development* 2002;129:443–453. [PubMed: 11807036]
63. Kidd AR 3rd, Miskowski JA, Siegfried KR, Sawa H, Kimble J. A beta-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling. *Cell* 2005;121:761–772. [PubMed: 15935762]
64. Huang S, Shetty P, Robertson SM, Lin R. Binary cell fate specification during *C. elegans* embryogenesis driven by reiterated reciprocal asymmetry of TCF POP-1 and its coactivator beta-catenin SYS-1. *Development* 2007;134:2685–2695. [PubMed: 17567664]
65. Phillips BT, Kidd AR 3rd, King R, Hardin J, Kimble J. Reciprocal asymmetry of SYS-1/beta-catenin and POP-1/TCF controls asymmetric divisions in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 2007;104:3231–3236. [PubMed: 17296929]
66. Shetty P, Lo MC, Robertson SM, Lin R. *C. elegans* TCF protein, POP-1, converts from repressor to activator as a result of Wnt-induced lowering of nuclear levels. *Dev Biol* 2005;285:584–592. [PubMed: 16112103]
67. Calvo D, Victor M, Gay F, Sui G, Luke MP, Dufourcq P, Wen G, Maduro M, Rothman J, Shi Y. A POP-1 repressor complex restricts inappropriate cell type-specific gene transcription during *Caenorhabditis elegans* embryogenesis. *Embo J* 2001;20:7197–7208. [PubMed: 11742996]
68. Maduro MF, Kasmir JJ, Zhu J, Rothman JH. The Wnt effector POP-1 and the PAL-1/Caudal homeoprotein collaborate with SKN-1 to activate *C. elegans* endoderm development. *Dev Biol* 2005;285:510–523. [PubMed: 16084508]
69. Labouesse M, Mango SE. Patterning the *C. elegans* embryo: moving beyond the cell lineage. *Trends Genet* 1999;15:307–313. [PubMed: 10431192]
70. Gaudet J, Mango SE. Regulation of organogenesis by the *Caenorhabditis elegans* FoxA protein PHA-4. *Science* 2002;295:821–825. [PubMed: 11823633]
71. Pauli F, Liu Y, Kim YA, Chen PJ, Kim SK. Chromosomal clustering and GATA transcriptional regulation of intestine-expressed genes in *C. elegans*. *Development* 2006;133:287–295. [PubMed: 16354718]
72. McGhee JD, Sleumer MC, Bilenky M, Wong K, McKay SJ, Goszczynski B, Tian H, Krich ND, Khattra J, Holt RA, Baillie DL, Kohara Y, Marra MA, Jones SJ, Moerman DG, Robertson AG. The ELT-2 GATA-factor and the global regulation of transcription in the *C. elegans* intestine. *Dev Biol* 2007;302:627–645. [PubMed: 17113066]
73. Roy PJ, Stuart JM, Lund J, Kim SK. Chromosomal clustering of muscle-expressed genes in *Caenorhabditis elegans*. *Nature* 2002;418:975–979. [PubMed: 12214599]
74. McGhee JD. The *C. elegans* intestine. *WormBook* 2007:1–36. [PubMed: 18050495]
75. Baugh LR, Hunter CP. MyoD, modularity, and myogenesis: conservation of regulators and redundancy in *C. elegans*. *Genes Dev* 2006;20:3342–3346. [PubMed: 17182863]

76. Mango SE. The *C. elegans* pharynx: a model for organogenesis. *WormBook* 2007;1–26. [PubMed: 18050503]
77. Fukushige T, Hawkins MG, McGhee JD. The GATA-factor *elt-2* is essential for formation of the *Caenorhabditis elegans* intestine. *Dev Biol* 1998;198:286–302. [PubMed: 9659934]
78. Fukushige T, Hendzel MJ, Bazett-Jones DP, McGhee JD. Direct visualization of the *elt-2* gut-specific GATA factor binding to a target promoter inside the living *Caenorhabditis elegans* embryo. *Proc Natl Acad Sci U S A* 1999;96:11883–11888. [PubMed: 10518545]
79. Neves A, English K, Priess JR. Notch-GATA synergy promotes endoderm-specific expression of *ref-1* in *C. elegans*. *Development* 2007;134:4459–4468. [PubMed: 18003741]
80. Romney SJ, Thacker C, Leibold EA. An iron enhancer element in the *FTN-1* gene directs iron-dependent expression in *Caenorhabditis elegans* intestine. *J Biol Chem* 2008;283:716–725. [PubMed: 18024960]
81. Fukushige T, Goszczynski B, Yan J, McGhee JD. Transcriptional control and patterning of the *pho-1* gene, an essential acid phosphatase expressed in the *C. elegans* intestine. *Dev Biol* 2005;279:446–461. [PubMed: 15733671]
82. Hawkins MG, McGhee JD. *elt-2*, a second GATA factor from the nematode *Caenorhabditis elegans*. *J Biol Chem* 1995;270:14666–14671. [PubMed: 7782329]
83. Kerry S, TeKippe M, Gaddis NC, Aballay A. GATA transcription factor required for immunity to bacterial and fungal pathogens. *PLoS ONE* 2006;1:e77. [PubMed: 17183709]
84. Shapira M, Hamlin BJ, Rong J, Chen K, Ronen M, Tan MW. A conserved role for a GATA transcription factor in regulating epithelial innate immune responses. *Proc Natl Acad Sci U S A* 2006;103:14086–14091. [PubMed: 16968778]
85. Schroeder DF, McGhee JD. Anterior-posterior patterning within the *Caenorhabditis elegans* endoderm. *Development* 1998;125:4877–4887. [PubMed: 9811572]
86. Hermann GJ, Schroeder LK, Hieb CA, Kershner AM, Rabbitts BM, Fonarev P, Grant BD, Priess JR. Genetic analysis of lysosomal trafficking in *Caenorhabditis elegans*. *Mol Biol Cell* 2005;16:3273–3288. [PubMed: 15843430]
87. Schroeder LK, Kremer S, Kramer MJ, Currie E, Kwan E, Watts JL, Lawrenson AL, Hermann GJ. Function of the *Caenorhabditis elegans* ABC transporter PGP-2 in the biogenesis of a lysosome-related fat storage organelle. *Mol Biol Cell* 2007;18:995–1008. [PubMed: 17202409]
88. Horner MA, Quintin S, Domeier ME, Kimble J, Labouesse M, Mango SE. *pha-4*, an HNF-3 homolog, specifies pharyngeal organ identity in *Caenorhabditis elegans*. *Genes Dev* 1998;12:1947–1952. [PubMed: 9649499]
89. Kalb JM, Lau KK, Goszczynski B, Fukushige T, Moons D, Okkema PG, McGhee JD. *pha-4* is *Cefkh-1*, a fork head/HNF-3 α , β , γ homolog that functions in organogenesis of the *C. elegans* pharynx. *Development* 1998;125:2171–2180. [PubMed: 9584117]
90. Okkema PG, Fire A. The *Caenorhabditis elegans* NK-2 class homeoprotein *CEH-22* is involved in combinatorial activation of gene expression in pharyngeal muscle. *Development* 1994;120:2175–2186. [PubMed: 7925019]
91. Okkema PG, Ha E, Haun C, Chen W, Fire A. The *Caenorhabditis elegans* NK-2 homeobox gene *ceh-22* activates pharyngeal muscle gene expression in combination with *pha-1* and is required for normal pharyngeal development. *Development* 1997;124:3965–3973. [PubMed: 9374394]
92. Thatcher JD, Fernandez AP, Beaster-Jones L, Haun C, Okkema PG. The *Caenorhabditis elegans* *peb-1* gene encodes a novel DNA-binding protein involved in morphogenesis of the pharynx, vulva, and hindgut. *Dev Biol* 2001;229:480–493. [PubMed: 11203704]
93. Raharjo I, Gaudet J. Gland-specific expression of *C. elegans* *hlh-6* requires the combinatorial action of three distinct promoter elements. *Dev Biol* 2007;302:295–308. [PubMed: 17049341]
94. Gaudet J, Muttumu S, Horner M, Mango SE. Whole-genome analysis of temporal gene expression during foregut development. *PLoS Biol* 2004;2:e352. [PubMed: 15492775]
95. Fukushige T, Brodigan TM, Schrieffer LA, Waterston RH, Krause M. Defining the transcriptional redundancy of early bodywall muscle development in *C. elegans*: evidence for a unified theory of animal muscle development. *Genes Dev* 2006;20:3395–3406. [PubMed: 17142668]
96. Krause M, Fire A, Harrison SW, Priess J, Weintraub H. *CeMyoD* accumulation defines the body wall muscle cell fate during *C. elegans* embryogenesis. *Cell* 1990;63:907–919. [PubMed: 2175254]

97. Fukushige T, Krause M. The myogenic potency of HLH-1 reveals wide-spread developmental plasticity in early *C. elegans* embryos. *Development* 2005;132:1795–1805. [PubMed: 15772130]
98. Fox RM, Watson JD, Von Stetina SE, McDermott J, Brodigan TM, Fukushige T, Krause M, Miller DM 3rd. The embryonic muscle transcriptome of *Caenorhabditis elegans*. *Genome Biol* 2007;8:R188. [PubMed: 17848203]
99. Kaletta T, Schnabel H, Schnabel R. Binary specification of the embryonic lineage in *Caenorhabditis elegans*. *Nature* 1997;390:294–298. [PubMed: 9384382]
100. Hunter CP, Kenyon C. Spatial and temporal controls target pal-1 blastomere-specification activity to a single blastomere lineage in *C. elegans* embryos. *Cell* 1996;87:217–226. [PubMed: 8861906]
101. Davidson EH, Rast JP, Oliveri P, Ransick A, Calestani C, Yuh CH, Minokawa T, Amore G, Hinman V, Arenas-Mena C, Otim O, Brown CT, Livi CB, Lee PY, Revilla R, Schilstra MJ, Clarke PJ, Rust AG, Pan Z, Arnone MI, Rowen L, Cameron RA, McClay DR, Hood L, Bolouri H. A provisional regulatory gene network for specification of endomesoderm in the sea urchin embryo. *Dev Biol* 2002;246:162–190. [PubMed: 12027441]
102. Hinman VF, Nguyen A, Davidson EH. Caught in the evolutionary act: precise cis-regulatory basis of difference in the organization of gene networks of sea stars and sea urchins. *Dev Biol* 2007;312:584–595. [PubMed: 17956756]
103. Wray GA. The evolutionary significance of cis-regulatory mutations. *Nat Rev Genet* 2007;8:206–216. [PubMed: 17304246]
104. An JH, Blackwell TK. SKN-1 links *C. elegans* mesendodermal specification to a conserved oxidative stress response. *Genes Dev* 2003;17:1882–1893. [PubMed: 12869585]
105. Schulze J, Schierenberg E. Cellular pattern formation, establishment of polarity and segregation of colored cytoplasm in embryos of the nematode *Romanomermis culicivorax*. *Dev Biol*. 2008
106. Wiegner O, Schierenberg E. Regulative development in a nematode embryo: a hierarchy of cell fate transformations. *Dev Biol* 1999;215:1–12. [PubMed: 10525346]
107. Kiontke K, Fitch DH. The phylogenetic relationships of *Caenorhabditis* and other rhabditids. *WormBook* 2005:1–11. [PubMed: 18050394]
108. Fukushige T, Goszczynski B, Tian H, McGhee JD. The Evolutionary Duplication and Probable Demise of an Endodermal GATA Factor in *Caenorhabditis elegans*. *Genetics* 2003;165:575–588. [PubMed: 14573471]
109. Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA. Transcriptional regulatory networks in *Saccharomyces cerevisiae*. *Science* 2002;298:799–804. [PubMed: 12399584]
110. Ward JJ, Thornton JM. Evolutionary models for formation of network motifs and modularity in the *Saccharomyces* transcription factor network. *PLoS Comput Biol* 2007;3:1993–2002. [PubMed: 17967049]
111. Felix MA. Cryptic quantitative evolution of the vulva intercellular signaling network in *Caenorhabditis*. *Curr Biol* 2007;17:103–114. [PubMed: 17240335]
112. Stein LD, Bao Z, Blasiar D, Blumenthal T, Brent MR, Chen N, Chinwalla A, Clarke L, Clee C, Coghlan A, Coulson A, D'Eustachio P, Fitch DH, Fulton LA, Fulton RE, Griffiths-Jones S, Harris TW, Hillier LW, Kamath R, Kuwabara PE, Mardis ER, Marra MA, Miner TL, Minx P, Mullikin JC, Plumb RW, Rogers J, Schein JE, Sohrmann M, Spieth J, Stajich JE, Wei C, Willey D, Wilson RK, Durbin R, Waterston RH. The Genome Sequence of *Caenorhabditis briggsae*: A Platform for Comparative Genomics. *PLoS Biol* 2003;1:E45. [PubMed: 14624247]
113. Zhao Z, Boyle TJ, Bao Z, Murray JI, Mericle B, Waterston RH. Comparative analysis of embryonic cell lineage between *Caenorhabditis briggsae* and *Caenorhabditis elegans*. *Dev Biol* 2008;314:93–99. [PubMed: 18164284]
114. Zauner H, Sommer RJ. Evolution of robustness in the signaling network of *Pristionchus* vulva development. *Proc Natl Acad Sci U S A* 2007;104:10086–10091. [PubMed: 17551021]
115. Loose M, Patient R. A genetic regulatory network for *Xenopus* mesendoderm formation. *Dev Biol* 2004;271:467–478. [PubMed: 15223347]
116. Swiers G, Patient R, Loose M. Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. *Dev Biol*. 2006

117. Gabriel WN, McNuff R, Patel SK, Gregory TR, Jeck WR, Jones CD, Goldstein B. The tardigrade *Hypsibius dujardini*, a new model for studying the evolution of development. *Dev Biol* 2007;312:545–559. [PubMed: 17996863]

FIG. 1.

The *C. elegans* endomesoderm gene regulatory network. Ovals represent transcription factors, while rectangles indicate other types of proteins. Question marks denote hypothesized co-regulators or functions. Arrows denote, in most cases, direct regulatory interactions. Thinner arrows denote contributions that are hypothesized to be weaker based on genetic evidence. Overlapping transcription factor symbols denote common function and are not meant to imply physical interaction. Diagrams of the *C. elegans* embryo (4-cell and 8-cell stages), and anatomy of the digestive tract in a larva are shown, after ref. [3], with anterior to the left, and dorsal upwards. Sections of the digestive tract are labeled with the name of the blastomere whose descendants contribute to that region. The association of 'anterior pharynx' with ABa, and

‘posterior pharynx’ with MS is in reality not a precise distinction [9] and is shown here as such for simplicity. GLP-1/Notch-dependent cell-cell interactions are shown as ‘Notch’ with an arrow [9].

FIG. 2.

Appearance of wild-type and zygotic cell fate specification mutants and associated expression of a *pha-4::GFP* reporter (pseudocolored yellow; a gift from Jeb Gaudet, University of Calgary). (A) Wild-type L1, showing pharynx and rectum (red) and intestine (blue) and associated blastomeres as in Fig. 1. (B) Arrested *end-1(ok558) end-3(ok1448)* double mutant embryo, showing absence of gut and slightly reduced body length as compared with wild-type larvae. The vast majority of *end-1,3(-)* embryos elongate within the eggshell, but only some of these hatch. A more detailed characterization of these mutants will be presented elsewhere. (C) Arrested *med-1(ok804); med-2(cx9744); end-1(ok558) end-3(ok1448)* quadruple-null mutant. The most severely affected *med-1,2(-)* embryos arrest lacking gut and at a similar

stage as the embryo shown here [25]. (D–F) Expression of *pha-4::GFP* in pharynx, rectum and intestine cells, corresponding to the DIC images in A–C. The hypodermis is indicated with a dotted blue line. Anterior is to the left in panels A, B, E and F, and up in panels C and F. All micrographs are shown at the same scale. In A–C, Adobe Photoshop was used to colorize regions. A *C. elegans* embryo is approximately 50µm along its long axis.

FIG. 3.

Speculative models for stepwise evolution of two extant motifs in the *C. elegans* endomesoderm network, starting with single activator, single target interactions. (A) Stepwise formation of the SKN-1 → MED-1,2 → TBX-35 regulatory chain. (B) Formation of a feed-forward loop involving SKN-1 and two ENDS. Note that autoregulation of the first *end* gene is inferred but this is not known for *end-1*. Intercalation of the MEDs could occur at an early or later step by acquisition of MED sites in the *end* genes (not shown).